Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Fulcrum Therapeutics (Nasdaq: FULC) announced inducement grants under Nasdaq Listing Rule 5635(c)(4) to new employees on October 6, 2025. The company granted an aggregate of 47,450 non-statutory stock options under its 2022 Inducement Stock Incentive Plan at an exercise price of $9.50 per share (closing price on the grant date).

Each option has a 10-year term and vests over four years: 25% after the first anniversary of employment and then 6.25% quarterly over the following twelve quarters, subject to continued service.

CAMBRIDGE, Mass., Oct. 10, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.^® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that the company granted non-statutory stock options to new employees. Fulcrum granted stock options to purchase shares of the company’s common stock pursuant to the company’s 2022 Inducement Stock Incentive Plan, as amended, or the plan, as an inducement material to the new employees entering into employment with Fulcrum in accordance with Nasdaq Listing Rule 5635(c)(4).

Fulcrum granted the new employees an aggregate of 47,450 options to purchase shares of the company’s common stock at an exercise price of $9.50 per share, the closing price per share of Fulcrum’s common stock as reported on the grant effective date, October 6, 2025. Each option has a ten-year term and vests over four years, with 25% of the original number of shares vesting on the first anniversary of the applicable employee’s start date and an additional 6.25% of the shares vesting in equal quarterly installments over the twelve successive quarters following the first anniversary, subject to the applicable employee’s continued service with the company through the applicable vesting dates.

About Fulcrum Therapeutics

Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum’s lead clinical program is pociredir, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease. Fulcrum uses proprietary technology to identify drug targets that can modulate gene expression to treat the known root cause of gene mis-expression. For more information, visit http://www.fulcrumtx.com and follow us on X (@FulcrumTx) and LinkedIn.

Contact:

Kevin Gardner
LifeSci Advisors, LLC
kgardner@lifesciadvisors.com
617-283-2856

FAQ

What did Fulcrum Therapeutics (FULC) grant on October 6, 2025?

Fulcrum granted an aggregate of 47,450 non-statutory stock options to new employees at an exercise price of $9.50 per share.

What are the key terms of the FULC inducement stock options?

Each option has a 10-year term and vests over four years with 25% after year one and 6.25% quarterly thereafter.

Why did Fulcrum issue these options under Nasdaq Rule 5635(c)(4)?

The options were granted as inducement awards material to new employees entering employment in accordance with Nasdaq Listing Rule 5635(c)(4).

How was the exercise price for FULC options determined?

The exercise price of $9.50 per share equals Fulcrum's closing common stock price on the grant effective date, October 6, 2025.

Will the FULC option grants dilute existing shareholders?

The filing lists 47,450 options; whether this is material dilution depends on Fulcrum's outstanding share count, which is not provided in this announcement.

Where can investors find more details about the FULC inducement grants?

Investors can review the company's SEC filings and investor relations disclosures for the full terms and any related exhibits.